Beam Therapeutics
Beam Therapeutics raises $206M Series C at $3.5B valuation
Quick Facts
Beam Therapeutics: Series C Funding Round
Beam Therapeutics has successfully raised $206M in Series C funding, reaching a valuation of $3.5B.
Company Overview
Base editing technology
Funding Details
The Series C round was led by Foresite Capital, with participation from F-Prime Capital, Omega Funds, Redmile Group, Wellington Management.
Company Information
- Headquarters: 238 Main Street, Cambridge, MA 02142
- Founded: 2017
- Employees: 400+
- Category: Biotech
Investment
Beam Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series C
- F-Prime Capital: Verified investor in Series C
- Omega Funds: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Wellington Management: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...